Cyclophosphamide Injection 1G


Indications and Reactions:

Role Indications Reactions
Primary
Diffuse Large B-cell Lymphoma 44.4%
Product Used For Unknown Indication 28.0%
B-cell Lymphoma 16.4%
Hodgkin's Disease 2.6%
Prophylaxis 0.9%
Breast Cancer 0.8%
Premedication 0.8%
Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis 0.7%
Bone Marrow Conditioning Regimen 0.7%
Constipation 0.7%
Prophylactic Chemotherapy 0.7%
Plasma Cell Myeloma 0.6%
Nausea 0.5%
Cancer 0.3%
Chronic Obstructive Pulmonary Disease 0.3%
Hypertension 0.3%
Non-hodgkin's Lymphoma Unspecified Histology Indolent 0.3%
Vomiting 0.3%
Abdominal Pain Lower 0.3%
Chronic Lymphocytic Leukaemia 0.3%
Malaise 24.4%
Infusion Related Reaction 20.9%
Death 12.2%
Cardiac Disorder 10.5%
Second Primary Malignancy 8.7%
Infection 4.1%
Neutropenic Sepsis 4.1%
Toxicity To Various Agents 2.3%
Sepsis 1.7%
Completed Suicide 1.2%
Lower Respiratory Tract Infection 1.2%
Neuropathy Peripheral 1.2%
Neurotoxicity 1.2%
Osteonecrosis 1.2%
Pyrexia 1.2%
Syncope 1.2%
Vomiting 1.2%
Aortic Aneurysm Rupture 0.6%
Disease Progression 0.6%
Drug Intolerance 0.6%
Secondary
Product Used For Unknown Indication 45.1%
Diffuse Large B-cell Lymphoma 9.8%
Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis 6.3%
Prophylactic Chemotherapy 6.3%
B-cell Lymphoma 5.5%
Premedication 4.3%
Constipation 3.1%
Nausea 3.1%
Prophylaxis 3.1%
Neuroblastoma 2.0%
Non-hodgkin's Lymphoma Unspecified Histology Indolent 1.6%
Abdominal Pain Lower 1.2%
Clear Cell Renal Cell Carcinoma 1.2%
Dyspepsia 1.2%
Plasma Cell Myeloma 1.2%
Pulmonary Embolism 1.2%
Uveitis 1.2%
Vomiting 1.2%
Abdominal Pain 0.8%
Anaemia 0.8%
Cardiac Disorder 25.0%
Tachycardia 9.4%
Aortic Aneurysm Rupture 6.3%
Death 6.3%
Disease Progression 6.3%
Intestinal Perforation 6.3%
Pneumonia 6.3%
Vomiting 6.3%
Drug Intolerance 3.1%
Neutropenia 3.1%
Oesophagitis 3.1%
Pyrexia 3.1%
Rash 3.1%
Rickets 3.1%
Sepsis 3.1%
Stomatitis 3.1%
Urinary Tract Infection 3.1%

Drug Data